Asia Pacific Sarcopenia Treatment Market Analysis

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Asia Pacific Sarcopenia Treatment Market Analysis

  • Pharmaceutical
  • Published Report
  • Nov 2023
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 223
  • No of Figures: 43

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE

2.8 MARKET END USER COVERAGE GRID

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL-

4.2 PORTER

5 REGULATIONS IN AUSTRALIA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF SARCOPENIA

6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH

6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR

6.2 RESTRAINTS

6.2.1 LACK OF STANDARDIZED DIAGNOSIS

6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

6.4 CHALLENGES

6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT

6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL

7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 VITAMIN/DIETARY SUPPLEMENTS

7.2.1 VITAMIN SUPPLEMENTS

7.2.2 PROTEIN SUPPLEMENTS

7.2.3 FATTY ACID SUPPLEMENTS

7.2.4 CREATINE

7.2.5 WHEY PROTEINS

7.2.6 L-CARNITINE

7.2.7 SOY

7.2.8 BETA-ALANINE

7.2.9 OSTARINE

7.2.10 COLLAGEN PEPTIDES

7.2.11 LIGANDROL

7.2.12 BRANCH-CHAIN AMINO ACIDS

7.2.13 HYDROXYMETHYLBUTYRATE (HMB)

7.2.14 MEDIUM CHAIN TRIGLYCERIDES

7.2.15 OTHERS

7.3 MEDICATIONS

7.3.1 OFF LABEL DRUGS

7.3.2 EMERGING DRUGS

7.3.2.1 ACE INHIBITORS

7.3.2.1.1 APPETITE STIMULANTS

7.3.2.1.2 ORAL ANTIDIABETIC DRUGS

7.3.2.1.3 OTHERS

7.4 OTHERS

8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 PRIMARY SARCOPENIA

8.2.1 VITAMIN/DIETARY SUPPLEMENTS

8.2.2 MEDICATIONS

8.2.3 OTHERS

8.3 SECONDARY SARCOPENIA

8.3.1 VITAMIN/DIETARY SUPPLEMENTS

8.3.2 MEDICATIONS

8.3.3 OTHERS

9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES

9.1 OVERVIEW

9.2 PRE-SARCOPENIA

9.3 SARCOPENIA

9.4 SEVERE SARCOPENIA

10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.3 INJECTABLES

10.4 OTHERS

11 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER

11.1 OVERVIEW

11.2 MALE

11.3 FEMALES

12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.2.1 PUBLIC

12.2.2 PRIVATE

12.3 SPECIALTY CLINICS

12.4 HOME HEALTHCARE

12.5 OTHERS

13 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

13.3.1 HOSPITAL PHARMACIES

13.3.2 ONLINE PHARMACIES

13.3.3 OTHERS

13.4 OTHERS

14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRIES

14.1 ASIA-PACIFIC

14.1.1 JAPAN

14.1.2 CHINA

14.1.3 SOUTH KOREA

14.1.4 INDIA

14.1.5 AUSTRALIA

14.1.6 SINGAPORE

14.1.7 THAILAND

14.1.8 MALAYSIA

14.1.9 INDONESIA

14.1.10 PHILIPPINES

14.1.11 VIETNAM

14.1.12 NEW ZEALAND

14.1.13 TAIWAN

1.3.1. REST OF ASIA-PACIFIC

15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, COMPANY

15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 ABBOTT

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.)

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENT

17.3 NOVARTIS AG

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 PIPELINE PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 SANOFI

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.5 HALEON GROUP OF COMPANIES.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENT

17.6 ASTAREAL CO., LTD.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 BASF SE

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 DSM

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 FERMENTA BIOTECH LIMITED

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENT

17.1 HEALING PHARMA INDIA PVT.IND.

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.11 METAGENICS

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENT

17.12 THE VITAMIN COMPANY INDIA

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.13 WELLONA PHARMA

17.13.1 COMPANY SNAPSHOT

17.13.2 PRODUCT PORTFOLIO

17.13.3 RECENT DEVELOPMENT

17.14 BIOPHYTIS

17.14.1 COMPANY SNAPSHOT

17.14.2 PIPELINE PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 IMMUNOFORGE INC.

17.15.1 COMPANY SNAPSHOT

17.15.2 PIPELINE PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 ONCOCROSS CO., LTD.

17.16.1 COMPANY SNAPSHOT

17.16.2 PIPELINE PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 OPKO HEALTH, INC.

17.17.1 COMPANY SNAPSHOT

17.17.2 REVENUE ANALYSIS

17.17.3 PIPELINE PORTFOLIO

17.17.4 RECENT DEVELOPMENT

17.18 REGENERON PHARMACEUTICALS INC.

17.18.1 COMPANY SNAPSHOT

17.18.2 REVENUE ANALYSIS

17.18.3 PIPELINE PORTFOLIO

17.18.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 ASIA-PACIFIC VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES , 2021-2030 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER , 2021-2030 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 15 JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 JAPAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 18 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 19 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 20 JAPAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 21 JAPAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 22 JAPAN PRIMARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 23 JAPAN SECONDARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 24 JAPAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 25 JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 26 JAPAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 27 JAPAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 28 JAPAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 29 JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 30 JAPAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 31 CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 32 CHINA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 33 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 34 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 35 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 36 CHINA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 37 CHINA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 38 CHINA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 CHINA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 40 CHINA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 41 CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 42 CHINA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 43 CHINA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 44 CHINA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 46 CHINA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 47 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 48 SOUTH KOREA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 51 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 52 SOUTH KOREA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 SOUTH KOREA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 55 SOUTH KOREA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 56 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 57 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 58 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 59 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 60 SOUTH KOREA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 62 SOUTH KOREA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 63 INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 64 INDIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 66 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 67 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 68 INDIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 69 INDIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 70 INDIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 INDIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 72 INDIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 73 INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 74 INDIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 75 INDIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 76 INDIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 78 INDIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 79 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 AUSTRALIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 83 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 84 AUSTRALIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 AUSTRALIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 AUSTRALIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 89 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 90 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 91 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 92 AUSTRALIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 93 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 94 AUSTRALIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 95 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 96 SINGAPORE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 97 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 99 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 100 SINGAPORE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 SINGAPORE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 SINGAPORE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 104 SINGAPORE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 105 SINGAPORE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 106 SINGAPORE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 107 SINGAPORE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 108 SINGAPORE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 SINGAPORE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 110 SINGAPORE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 111 THAILAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 THAILAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 115 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 116 THAILAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 117 THAILAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 THAILAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 THAILAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 THAILAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 121 THAILAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 122 THAILAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 123 THAILAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 124 THAILAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 THAILAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 126 THAILAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 127 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 MALAYSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 129 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 130 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 131 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 132 MALAYSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 134 MALAYSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 135 MALAYSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 136 MALAYSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 137 MALAYSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 138 MALAYSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 139 MALAYSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 140 MALAYSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 MALAYSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 142 MALAYSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 143 INDONESIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 INDONESIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 147 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 148 INDONESIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 INDONESIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 INDONESIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 INDONESIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 152 INDONESIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 153 INDONESIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 154 INDONESIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 155 INDONESIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 156 INDONESIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 INDONESIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 158 INDONESIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 159 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 PHILIPPINES MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 162 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 163 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 164 PHILIPPINES VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 165 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 PHILIPPINES PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 PHILIPPINES SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 168 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 169 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 170 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 171 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 172 PHILIPPINES HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 174 PHILIPPINES RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 VIETNAM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 VIETNAM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 179 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 180 VIETNAM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 VIETNAM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 VIETNAM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 VIETNAM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 184 VIETNAM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 185 VIETNAM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 186 VIETNAM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 187 VIETNAM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 188 VIETNAM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 189 VIETNAM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 190 VIETNAM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 191 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 192 NEW ZEALAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 195 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 196 NEW ZEALAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 NEW ZEALAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 NEW ZEALAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 200 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 201 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 202 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 203 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 204 NEW ZEALAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 206 NEW ZEALAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 207 TAIWAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 208 TAIWAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 209 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 211 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 212 TAIWAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 TAIWAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 TAIWAN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 TAIWAN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 216 TAIWAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 217 TAIWAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 218 TAIWAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 219 TAIWAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 220 TAIWAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 TAIWAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 222 TAIWAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 223 REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

List of Figure

FIGURE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID

FIGURE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030

FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SARCOPENIA MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET

FIGURE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022

FIGURE 15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 16 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)

FIGURE 17 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 18 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2022

FIGURE 19 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 20 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 21 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2022

FIGURE 23 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)

FIGURE 24 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 25 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 26 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 27 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 28 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 29 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2022

FIGURE 31 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 32 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 33 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 34 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2022

FIGURE 35 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 36 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 40 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 41 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 43 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%)

Frequently Asked Questions

The Asia-Pacific Sarcopenia Treatment Market will be worth USD 861,882.42 thousand by 2030 during the forecast period.
The Asia-Pacific Sarcopenia Treatment Market growth rate is 5.9% during the forecast period.
Rising Prevalence of Sarcopenia & Growing Awareness of Sarcopenia and its Detrimental Effects on Health are the growth drivers of the Asia-Pacific Sarcopenia Treatment Market.
The treatment type, type, stages, route of administration, gender, end user, and distribution channel are the factors on which the Asia-Pacific Sarcopenia Treatment Market research is based.
Major companies in the Asia-Pacific Sarcopenia Treatment Market are Abbott., Nestlé Health Science ( A subsidary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma.